You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,072,697


✉ Email this page to a colleague

« Back to Dashboard


Title:Composition and method for treating neurological disease
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Filing Date:Jan 07, 2015
Application Number:14/591,641
Claims:1. A method comprising: orally administering to a human subject with Parkinson's disease once-daily a composition consisting of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient, wherein at least 50% of the drug in the composition is in an extended release form, and wherein the composition has an in vitro dissolution profile ranging between 35% and 55% in 2 hours, 60% and 80% in 4 hours, and greater than 90% in 8 hours using a USP type 2 (paddle) dissolution system at 50 rpm at a temperature of 37.+-.0.5.degree. C. in water, and wherein the daily dose of drug administered to the human subject is 200 to 500 mg.

2. A method comprising: orally administering to a human subject with Parkinson's disease once-daily a composition consisting of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient, wherein at least 50% of the drug in the composition is in an extended release form and the extended release form of the composition has an in vitro dissolution profile ranging between 35% and 55% in 2 hours, 60% and 80% in 4 hours, and greater than 90% in 8 hours using a USP type 2 (paddle) dissolution system at 50 rpm at a temperature of 37.+-.0.5.degree. C. in water, and wherein the daily dose of drug administered to the human subject is 200 to 500 mg.

3. A method comprising: orally administering to a human subject with Parkinson's disease once-daily a composition consisting of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient, wherein at least 50% of the drug in the composition is in an extended release form and the extended release form of the composition has an in vitro dissolution profile ranging between 60% and 80% in 4 hours, and greater than 90% in 8 hours using a USP type 2 (paddle) dissolution system at 50 rpm at a temperature of 37.+-.0.5.degree. C. in water, and wherein the daily dose of drug administered to the human subject is 200 to 500 mg.

4. The method of any one of claims 1 to 3, wherein the daily dose of drug administered is 300 to 500 mg.

5. The method of any one of claims 1 to 3, wherein at least 75% of the drug in the composition is in an extended release form.

6. The method of any one of claims 1 to 3, wherein at least 90% of the drug in the composition is in an extended release form.

7. The method of any one of claims 1 to 3, wherein at least some of the drug is in an immediate release form.

8. The method of any one of claims 1 to 3, wherein the dose administered is therapeutically effective for the treatment of Parkinson's disease.

9. The method of any one of claims 1 to 3, wherein the human subject with Parkinson's disease suffers from dyskinesia.

10. The method of claim 9, wherein the method reduces the frequency or severity of dyskinesia.

11. The method of claim 9, wherein the dyskinesia is levodopa-induced dyskinesia.

12. The method of any one of claims 1 to 3, additionally comprising administering to the subject a pharmaceutically effective amount of levodopa/carbidopa.

13. The method of any one of claims 1 to 3, wherein the composition provides a shift in amantadine Tmax of 2 hours to 16 hours relative to an immediate release form of amantadine, wherein the Tmax is measured in a single dose human pharmacokinetic study.

14. The method of any one of claims 1 to 3, wherein the extended release form comprises an osmotic device which utilizes an osmotic driving force to provide extended release of the drug.

15. The method of any one of claims 1 to 3, wherein the extent of drug bioavailability is maintained.

16. The method of any one of claims 1 to 3, wherein the once-daily administration of the composition is at a therapeutically-effective dose from the onset of therapy.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.